ESPERION THERAPEUTICS INC. - COMMON STOCK

Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

01 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders

25 May 2023 16:30:00 By Nasdaq GlobeNewswire

Esperion to Participate in Jefferies Healthcare Conference

24 May 2023 08:00:01 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

12 May 2023 16:30:00 By Nasdaq GlobeNewswire

Esperion Reports First Quarter 2023 Financial Results

09 May 2023 07:00:02 By Nasdaq GlobeNewswire

Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9

04 May 2023 08:30:00 By Nasdaq GlobeNewswire

Esperion to Participate in JMP Securities Life Sciences Conference

01 May 2023 08:00:01 By Nasdaq GlobeNewswire

Esperion to Participate in Bank of America Securities 2023 Health Care Conference

27 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Esperion to Report First Quarter 2023 Financial Results May 9, 2023

25 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC

19 Apr 2023 08:42:01 By Nasdaq GlobeNewswire

Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference

03 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

22 Mar 2023 16:15:00 By Nasdaq GlobeNewswire

Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

20 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk

08 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients

04 Mar 2023 10:30:00 By Nasdaq GlobeNewswire

Esperion Launches New Scientific Website

24 Feb 2023 13:40:00 By Nasdaq GlobeNewswire

Esperion to Participate in the Cowen 43rd Annual Healthcare Conference

23 Feb 2023 08:00:02 By Nasdaq GlobeNewswire

CLEAR Outcomes Company Update Call: Detailed Results Discussion

22 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

21 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC

20 Feb 2023 08:00:00 By Nasdaq GlobeNewswire